ABCELLERA BIOLOGICS Working Capital to Net Assets Ratio
ABCELLERA BIOLOGICS working capital to net assets ratio. ABCELLERA BIOLOGICS (8QQ) has a Working Capital to Net Assets ratio of 69.9% as of June 2026. Working capital of €626.04 Million (current assets of €679.23 Million minus current liabilities of €53.19 Million) is measured against net assets of €896.02 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ABCELLERA BIOLOGICS (8QQ) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of ABCELLERA BIOLOGICS (2021–2025)
Working capital to net assets ratio of ABCELLERA BIOLOGICS from 2021 to 2025. This chart shows how ABCELLERA BIOLOGICS's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 69.9%, reflecting working capital of €626.04 Million against net assets of €896.02 Million EUR. See ABCELLERA BIOLOGICS defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
ABCELLERA BIOLOGICS Working Capital to Net Assets Ratio by Year (2021–2025)
ABCELLERA BIOLOGICS working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for ABCELLERA BIOLOGICS from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 8QQ asset base.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 68.7% | €663.92 Million | €966.90 Million | €728.23 Million | €64.31 Million | ▲ +4.8 pp |
| 2024 | 63.9% | €674.76 Million | €1.06 Billion | €751.37 Million | €76.61 Million | ▼ -1.5 pp |
| 2023 | 65.3% | €752.97 Million | €1.15 Billion | €871.99 Million | €119.01 Million | ▼ -8.2 pp |
| 2022 | 73.6% | €907.17 Million | €1.23 Billion | €1.03 Billion | €118.32 Million | ▼ -5.3 pp |
| 2021 | 78.9% | €809.12 Million | €1.03 Billion | €929.80 Million | €120.68 Million | — |